Multisystem atrophy (MSA) is a sporadic progressive neurodegenerative disease that is manifested by a combination of autonomic and motor dysfunctions: parkinsonism, cerebellar ataxia, pyramidal syndrome, etc. Given the complexity of the diagnosis, the clinical polymorphism and the ignorance of neurologists about this disease, patients are often followed up by doctors of other profile or are observed with an incorrect diagnosis. There are two main MCA phenotypes – predominant cerebellar ataxia (MSA-C) and predominant parkinsonism (MSA-P), which are determined by the localization of the affected structures and the dominance of certain clinical symptoms. This article presents three clinical cases with different subtypes of MSA. Despite the difference in clinical manifestations, all patients was diagnosed with clinically established MSA. The features of the collection of complaints and anamnesis are described, the analysis of the neurological status and characteristic neuroimaging markers that can help in the differential diagnosis of this rare disease is carried out.
Multiple system atrophy (MSA) is a rare, sporadically occurring neurodegenerative disease with a progressive course. MSA is characterized by a combination of autonomic dysfunction and motor disturbances, including parkinsonian syndrome, cerebellar ataxia, pyramidal symptoms, and other manifestations. Diagnosis of this disease is often challenging due to the diversity of clinical presentations and insufficient awareness among neurologists, which can lead to misdiagnosis or patients being monitored by specialists in other fields. Depending on the predominant symptoms and the localization of lesions in the central nervous system, two main clinical variants of MSA are distinguished: parkinsonian (MSA-P) and cerebellar (MSA-C). This article presents important current preclinical and clinical studies focused on slowing the progression of MSA, including drugs targeting pathological α-synuclein, as well as neuroprotective and anti-inflammatory approaches. Current data on studies of drugs aimed at symptomatic treatment of MSA are also presented.